Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

BioAegis announces promising data in case study involving critical COVID-19 patient

By Brian Buntz | August 27, 2021

BioAegisBioAegis (North Brunswick, NJ) is evaluating data from a Phase 2 clinical trial related to recombinant human plasma gelsolin (rhu-pGSN) along with standard of care in treating patients with severe COVID-19 pneumonia.

In the interim, the company has announced the results of a compassionate use case study involving a hospitalized patient with critical COVID-19 pneumonia. The study was published in Clinical Infection in Practice.

“While a single case study does not prove efficacy of our treatment, it was gratifying to observe a rapid and complete recovery of a patient with critical COVID pneumonia,” said study co-author and BioAegis’ chief medical officer, Dr. Mark DiNubile, in a statement. “The maximum benefit of immunotherapies, like gelsolin, appears to be in the sickest patients where there is an overexuberant inflammatory response.”

Gelsolin is a naturally occurring actin-binding protein that can become depleted in people infected with SARS-CoV-2.

The study involved a 73-year-old generally healthy woman who required intubation and sedation upon the fifth day of hospitalization for COVID-19 pneumonia. Her blood pressure dropped to a level necessitating pressor drugs for 36 hours, at which point clinicians administered three doses of rhu-pGSN. Ultimately, the patient’s blood pressure stabilized without the need for antihypotensive vasopressors. The patient also received antibiotics.

Five days after the rhu-pGSN therapy, the patient was extubated and stopped antibiotic treatment.

On the fifth day after gelsolin treatment, she was extubated, and antibiotics were discontinued.

The company finished recruitment for its Phase 2 COVID-19 study in March.

Earlier this year, BioAegis won a contract from Biomedical Advanced Research and Development Authority (BARDA), a division of HHS related to the development of a therapy for severe sepsis.

The company is also pursuing treatments for idiopathic bronchiectasis, neuroinflammation, arthritis and lupus nephritis.


Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: BioAegis, gelsolin, rhu-pGSN, SARS-CoV-2
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE